DiaMedica Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DiaMedica Therapeutics Inc.
In the latest venture capital and private equity funding deals in China, SanegeneBio, Argo Biopharma and Ausper Biopharma raised a combined $136m on the back of their early-stage small interfering RNA and antisense oligonucleotide assets.
Roughly $130m was raised in eight biopharma financings in China over the past months that were backed by venture capital investors.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
- Large Molecule
- Other Names / Subsidiaries
- Sanomune Inc.
- DiaMedica Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.